Generation of induced neural stem cells with inducible IDH1.sup.R132H for analysis of glioma development and drug testing

• Published in: PloS one 2020-09, Vol.15 (9), p.e0239325
• Main Authors: Rosiak-Stec, Kamila, Grot, Dagmara, Rieske, Piotr
• Format: Article
• Language: English
• Subjects: Care and treatment; Development and progression; Drug discovery; Gene mutation; Genetic aspects; Gliomas; Health aspects; Innovations; Isocitrate dehydrogenase
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0239325

Mutation in isocitrate dehydrogenase 1 (IDH1.sup.R132H) occurs in various types of cancer, including low and high grade gliomas. Despite high incidence indicating its central role in tumor initiation and progression there are no targeted therapies directed against this oncogene available in the clinic. This is due to the limited understanding of the role of IDH1.sup.R132H in carcinogenesis, which is further propagated by the lack of appropriate experimental models. Moreover, proper in vitro models for analysis of gliomagenesis are required. In this study, we employed a Tet On system to generate human induced neural stem cells with doxycycline-inducible IDH1.sup.R132H . Equivalent expression of both forms of IDH1 in the presented model remains similar to that described in tumor cells. Additional biochemical analyses further confirmed tightly controlled gene regulation at protein level. Formation of a functional mutant IDH1 enzyme was supported by the production of D-2-hydroxyglutarate (D2HG). All samples tested for MGMT promoter methylation status, including parental cells, proved to be partially methylated. Analysis of biological effect of IDH1.sup.R132H revealed that cells positive for oncogene showed reduced differentation efficiency and viability. Inhibition of mutant IDH1 with selective inhibitor efficiently suppressed D2HG production as well as reversed the effect of mutant IDH1 protein on cell viability. In summary, our model constitutes a valuable platform for studies on the molecular basis and the cell of origin of IDH-mutant glioma (e.g. by editing P53 in these cells and their derivatives), as well as a reliable experimental model for drug testing.